The 22q11.2 microdeletion is one of the highest genetic risk factors for schizophrenia. It is not well understood which interactions of deleted genes in 22q11.2 regions are responsible for the pathogenesis of schizophrenia, but catechol-Omethytransferase (COMT) is among the candidates. Df1/ þ mice are 22q11.2 deletion syndrome (22q11DS) model mice with a hemizygous deletion of 18 genes in the 22q11-related region. Df1/ þ mice showed enhanced response to the dopamine D1 agonist, SKF38393, and the N-methyl-D-aspartate antagonist, MK801, which can be normalized by a GABA A receptor agonist, bretazenil, or a GABA A a2/a3 receptor agonist, SL651498. Here, we demonstrated the curing effects of virus-mediated reintroduction of Comt to the prefrontal cortex (PFC) in Df1/ þ mice. In contrast, both Comt overexpression and Comt inhibition caused an abnormal responsiveness to Bretazenil, a GABA A receptor agonist in control mice. Comt overexpression increased MK801-induced interneuronal activation and GABA release in the PFC. The expression levels of GABA-related genes such as Gabrb2 (GABA A receptor b2), Gad2 (glutamic acid decarboxylase 65 (Gad65)) and Reln (Reelin) correlate with a Comt expression level in PFC. Our data suggest that Comt-mediated regulation of GABAergic system might be involved in the behavioral pathogenesis of Df1/ þ mice.
Introduction
The 22q11.2 deletion syndrome (22q11DS) is known to be one of the highest risk factors for developing schizophrenia, and approximately one-fourth of 22q11DS patients develop schizophrenia. [1] [2] [3] All of the genes, except for one gene in human 22q11.2 region, exist on mouse chromosome 16. 4 Mice with a hemizygous deletion of 22q11.2-related region show schizophrenia-related behavioral abnormalities such as working memory deficits and sensory information-processing deficits. 5, 6 These animal models of 22q11DS provide an opportunity to explore possible therapeutic strategies for this specific subtype of schizophrenia. The 22q11.2 deletion contains 35 known genes at least. However, it is not known which of these genes are responsible for the psychiatric disorders of 22q11DS. The cumulative effects of the deletion of more than one gene might be responsible for the increased risk for schizophrenia of 22q11.2 DS. An epistatic interaction between two genes in 22q11.2 region, proline dehydrogenase (Prodh) and catechol-O-methyltransferase (Comt), has been reported. 7 Pharmacological inhibition of Comt activity exacerbates behavioral abnormalities of Prodh knockdown mice. 7 Comt is an enzyme that methylates catechol structures of dopamine (DA), norepinephrine (NE), caffeine and catechol estrogens. Comt plays a pivotal role in DA metabolism, specifically in the prefrontal cortex (PFC), because DA transporter is expressed in other brain regions, such as a striatum, and eliminates released DA even in the absence of Comt. 8, 9 In Comt knockout (KO) male mice, two-to three-fold increases in DA were observed specifically in the PFC but not in other brain regions, and NE levels were not affected, 10 because the NE transporter is abundant in the PFC. 11, 12 Administration of tolcapone, a specific brain-penetrant COMT inhibitor, causes an accumulation of 3,4-dihydroxy-phenylacetic acid (DOPAC) but has no effect on extracellular DA and NE, specifically in the PFC. 13 Human genetic studies of functional polymorphisms of Comt such as Val 158 Met have suggested that deficiency in COMT activity might reduce cognitive function and cause psychiatric symptoms in 22q11DS, [14] [15] [16] [17] although other studies have reported controversial results. [18] [19] [20] This might be caused by U-shaped effects of PFC DA level on cognitive functions. 21, 22 Animal model studies using COMToverexpressing transgenic mice and Comt KO mice have confirmed these complex effects of PFC DA levels, and have shown that either too little or too much DA in the PFC has impaired the PFC functions such as working memory and recognition memory. 23 Comt is known to be also expressed in embryonic mouse brain, 24 and DA receptor KO mice show abnormal morphology of dendrites of PFC projection neurons, increased parvalbumin expression in PFC interneurons and reduced mesencephalic dopaminergic neurons. 25, 26 These data might suggest a possibility that Comt affects working memory and recognition memory through the regulation of neurodevelopmental process. To address whether adult functions of Comt is responsible for behavioral defects in Df1/ þ mice, one of 22q11DS model mice, 5 we examined the therapeutic potential of lentivirus-mediated Comt overexpression in the adult PFC of Df1/ þ mice.
Materials and methods
Generation and genotyping of Dgcr2 KO mice. Dgcr2 genomic fragments were cloned by screening of a phage library containing 129/Sv mouse DNA fragment. To construct a targeting with a 5.6-kb 5 0 -recombinogenic arm and a 1.2-kb 3 0 -recombinogenic arm, EGFP-SV40-polyA-a neomycin phosphotransferase-expressing cassette (EGFP-Neo) -was inserted between SmaI and XhoI in exon 1 to replace the region between the two restriction sites. A dyphtheria toxin A-expressing cassette was flanked outside the 3 0 homologous region. The vector was linearized by restriction digestion and used to transfect embryonic stem cell line E14 by electroporation. Transfected cells were cultured in the presence of G418. Upon successful targeting, the neomycin expression cassette replaced exon 1 and the initiation codon of all the transcripts of Dgcr2. Therefore, it is expected to disrupt all Dgcr2 transcripts ( Figure 2 ). Correct targeting through homologous recombination in embryonic stem cells was confirmed by PCR and Southern blot. PCR for the KO allele was performed using the following primers: wild-type forward primer 5 0 -TTCCTGCTGGTTCTCACTGT-3 0 , reverse primer 5 0 -TCAAGGTCCCATTACTCCCTC-3 0 and neo primer 5 0 -TATTGCTGAAGAGCTTGGCG-3 0 . The wild-type allele produces a 1.6-kb band, whereas the targeted allele produces a 1.4-kb band. For Southern blotting, isolated genomic DNA was digested with EcoRI. The 7.5 and 5.8 kb fragments corresponding to the wild-type and KO allele were identified by hybridization with the 5 0 internal probe (Probe A, Figure 2b ).
Animals. Generation of Df1/ þ 22q11DS model mice was previously described in detail. 5, 27 Mice were maintained on the C57Bl/6 genetic background for at least 11 generations. Male, 2-3-month-old mice were used for behavioral analysis. Mouse colonies were maintained in accordance with the protocols approved by the Committee on Animal Research at Research Institute, Shiga Medical Center.
Reverse transcription PCR (RT PCR) analysis. The following primers were used to amplify target: Dgcr2; 5 0 -TTCCTGC TGGTTCTCACTG-3 0 and 5 0 -GTGGAGAAGGTAGCAAGT GA-3 0 ; b-actin; and Mouse b-Actin Control Amplimer Set (Clontech, Mountain View, CA, USA).
Cloning and production of lentiviral vectors. Cytomegalovirus (CMV)-IE/chicken b-actin promoter (CAG), 1.6-kb fragment cut from pXCAG, mouse a-calcium/ calmodulin-dependent protein kinase II (CaMKII) promoter 1.2-kb fragment and mouse membrane-bound-type Comt were introduced to FUGW lentiviral vector and lentiviruses were produced as previously described. 28 Briefly, human embryonic kidney 293T cells were transfected by using the Lipofectamine 2000 (Invitrogen, Tokyo, Japan) with the lentiviral vector and two helper plasmids, D8.9 and VSVG. After 48 h, the supernatants were spun at 780 Â g for 5 min, filtered through a 0.45 mm pore size filter (Millipore, Billerica, MA, USA) to remove cell debris, spun at 83 000 Â g for 1.5 h, and the pellet was resuspended in 100 ml of phosphatebuffered saline. For virus titration, HEK293T cells were infected with lentiviruses in decreasing concentrations. At 72 h after infection, cells were fixed in 4% paraformaldehyde and lentivirus-mediated Comt/EGFP expression was estimated by immunofluorescent analysis. Concentrated lentiviral titers ranged from 1 Â 10 8 to 1 Â 10 9 transducing units (TU) per ml.
Stereotaxic surgery. Injections of lentiviruses were performed stereotaxically in 8-to 10-week-old mice.
Mice were anesthetized using 2.5% Avertin solution and stereotaxic surgery was performed under standard conditions. The coordinate of the injection site was 2.0 mm anterior and 0.70 mm lateral to bregma at a depth of 1.75 and 2.25 mm at an 81 angle, and 2.4 mm anterior and 0.50 mm lateral to bregma at a depth of 1.13 mm at an 81 angle. All procedures were performed according to the guidelines on animal experiments of Shiga Medical Center. A total of 0.5 ml of purified virus was delivered on each side over a 3-min period. Lentivirusinfected mice were used for experiments at least 2 weeks after surgical operations for recovery. For verification of injection sites, 30 mm thick sections were cut using a cryostat at the level of PFC. Lentivirus infection was verified by immunohistochemical analysis of Comt for Lenti-CAG Comt or LentiCaMKII-Comt vector, and EGFP for Lenti-CAG-GFP vector.
Open field test. Locomotor activity was measured in the open field activity chambers (40 Â 40 Â 40 cm) equipped with photocells (beam spacing 2.5 cm) for the automatic recording of horizontal and vertical activity. Stereotypy count was analyzed using the VersaMax system (Accuscan Instruments, Columbus, OH, USA). Stereotypy was recorded when the mouse broke the same beams repeatedly. Stereotypy count is the number of beam breaks during stereotypic activity. Data were collected for 60 min.
Quantification of prefrontal cortical catecholamines and their metabolites. The mice were decapitated 2 weeks after lentiviral infection and the brains were quickly removed. Wet prefrontal cortical tissues were homogenized in two volumes of 0.2 M perchloric acid buffer containing 100 mM EDTA 2Na and 1 mg ml À1 isoproterenol as an internal standard (500 ml per 100 mg wet weight tissue) and kept on ice for 30 min. Homogenates were centrifuged at 15 000 r.p.m. for 15 min at 4 1C. The supernatants were collected, adjusted to pH 3 with 3M CH 3 COONa and analyzed by the high-performance liquid chromatography system with an electrochemical detector (HTEC-500, Eicom, Kyoto, Japan) for the analysis of DA, DOPAC, homovanillic acid (HVA), serotonin and 5-hydroxyindoleacetic acid (5-HIAA). The column used for separation was a SC-5ODS (Eicom). The mobile phase was 0.1 M sodium phosphate buffer (0.1 M NaH2PO4:0.1 M Na2HPO4 ¼ 1000:160, v/v), 1% methanol, 500 mg l À1 sodium sulfonate, and 50 mg l À1 EDTA.
Cannula implantation. The mice were anesthetized with 2.5% Avertin solution and stereotaxic surgery was performed under standard conditions. The guide cannula (AG-2, Eicom) with length 2 mm, inner diameter 0.4 mm and outer diameter 0.5 mm was implanted into the PFC (A þ 2.2 mm, L 0.5 mm and V 1 mm from the bregma) and fixed to the skull with dental cement. Following surgery, the animals were returned to their home cage and allowed to recover for 1 day before beginning of the experiment. using a microperfusion pump (ESP-32, Eicom) via a swivel system (Eicom), allowing the mice to move freely in a Plexiglas box (30 cm Â 30 cm Â 40 cm). The dialysate collected for the first 2 h was discarded to ensure a stable baseline of DA and g-aminobutyric acid (GABA) release. The DA content in the dialysate was quantified in the same way as for tissue homogenates. GABA content in the dialysate was quantified by high-performance liquid chromatography with electrochemical detector after derivatization of the amino acids with o-phthaldialdehyde (OPA) and 2-mercaptoethanol solution (Eicom). A total of 20 ml samples of perfusate were collected at 20 min intervals. One volume (5 ml) of 4 mM OPA was added to three volumes of dialysate and allowed to react for 2.5 min at room temperature. Then, the sample of the perfusate/OPA solution was injected into the high-performance liquid chromatography/electrochemical detector with a graphite electrode set at 600 mV against an Ag/AgCl reference electrode (Eicom). GABA was separated on SC-5 ODS column (2.1 mm Â 150 mm, Eicom). The mobile phase consisted of 0.1 M phosphate buffer, 0.013 mM EDTA 2Na, pH 6.0, with 30% MeOH pumped at a flow rate of 0.23 ml min À1 . The basal output was defined as the average of three samples before drug administration. The results were calculated as percentage of the baseline output of DA and GABA.
Immunohistochemical analysis. Mice were injected with MK801 (0.32 mg kg À1 ) intraperitoneally (i.p.) 2 h before killing for immunohistochemical analysis of c-Fos staining. Mice were perfused transcardially by 4% paraformaldehyde and 0.05% glutalaldehyde. The serial 30 mm cryostat sections were incubated with primary antibodies for 24 h at 4 1C after blocking for 30 min at room temperature with 5% donkey serum (Chemicon, Temecula, CA, USA) and for 1 h at room temperature with secondary antibodies (Molecular Probes, Eugene, OR, USA, and Vector Labs, Burlingame, CA, USA). The primary antibodies used were anti-Comt (Santa Cruz, Santa Cruz, CA, USA), anti-S100b (Sigma-Aldrich, St Louis, MO, USA), anti-NeuN (Chemicon), anti-c-Fos (Ab5, Calbiochem, San Diego, CA, USA), anti-GABA (GB69, Sigma-Aldrich) and anti-Gad67 (Chemicon). Peroxidase activity was visualized by Vectastatin Elite ABC Kit (Vector Labs). Slides were examined with a Zeiss microscope (Axiovert200M) (Zeiss, Tokyo, Japan) or an Olympus confocal laser scanning microscope (FV-300, Olympus, Tokyo, Japan). For the quantification of c-Fos-positive cells, the locations of prelimbic cortices of the PFC were defined according to the mouse brain in stereotaxic coordinates (2001, Academic Press, San Diego, CA, USA). The c-Fos-immunoreactive cells in the regions of interest were counted bilaterally in four serial sections matched for rostocaudal level by bregma distance per mice. For the quantification of Gad67 and GABA immunofluorescence, the perisomatic (puncta rings) or neuropil areas were delineated and then pixel density within the delineated area was calculated and averaged as described previously. At least four sections from four mice were analyzed.
Quantitative RT-PCR. Complementary DNA was obtained using a PrimeScript 1st strand cDNA synthesis kit (Takara, Shiga, Japan). Intron spanning Taqman probes were designed using the Roche Universal Probe Library method. Amplifications were run in a LightCycler 480 system (Roche, Tokyo, Japan). All data were analyzed using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) levels as reference.
The following primers were employed: Gabrb2, 
Results
Enhanced responsiveness to MK801 of Df1/ þ mice was normalized by GABA A receptor agonists. The DA agonists and N-methyl-D-aspartate receptor (NMDAR) antagonists such as Dizocilpine (MK801) are known to have psychometric effects on healthy individuals, and exacerbate symptoms of schizophrenia patients. [29] [30] [31] In Df1/ þ mice, the locomotor response to MK801 treatment (0.32 mg kg À1 ) was significantly enhanced (genotype-by-time interaction on the distance traveled, F 11, 165 ¼ 5.60, n ¼ 6-11 per group, Po0.0001 (repeated two-way analysis of variance (ANOVA); Figure 1a) . One of the primary pathologies observed in schizophrenia is a deficit in GABA signaling. [32] [33] [34] At first, to investigate a possible involvement of GABA signaling in the behavioral abnormality of Df1/ þ mice, we examined the effect of a nonselective GABA A partial receptor agonist, bretazenil. Bretazenil at 10 mg kg À1 normalized the enhanced response of Df1/ þ mice to MK801 (Df1/ þ mice: MK801 and bretazenil treatment; 4553.00±1307.28 cm, MK801 treatment; 10825.50 ± 1372.96 cm, n ¼ 6-7 per group, P ¼ 0.0071; Figures 1a-c). In contrast, in control mice, bretazenil had no effect on the traveled distance during 60 min after administration (control mice: MK801 and Next, to analyze which type of GABA A receptor is responsible for this reversing effect of bretazenil, Df1/ þ mice were treated with selective GABA agonists. SL651498, a selective agonist of GABA A a2/a3 receptor, but neither zolpidem, a selective agonist of GABA A a1 receptor, nor L655708, a selective inverse agonist of GABA A a5 receptor, specifically reversed the enhanced response of Df1/ þ mice to MK801 (ambulatory distance for 60 min after administration of drugs: control mice; MK801 and SL651498 1 mg kg À1 treatment, 6580.75±1499.15 cm, MK801 treatment, 7359.18±1586.83 cm, n ¼ 8-11 per group, P ¼ 0.73, Df1/ þ mice; MK801 and SL651498 1 mg kg À1 treatment, 4332.44±1229.75 cm, MK801 treatment, 10 825.50±1372.96 cm, n ¼ 6-9 per group, P ¼ 0.0043; Figures 1d-g ). Taken together, our data demonstrated that Df1/ þ mice show high responsiveness to MK801 like human schizophrenic patients, and the GABAergic transmission through GABA A a2/a3 receptor may be involved in this abnormal behavioral phenotype of Df1/ þ mice.
However, the deleted region of Df1/ þ mice is smaller than 1.5-Mb deletion found in human 22q11DS, which does not include Dgcr2 (Figure 2a) . Recently, it has been reported that a potentially destructive de-novo mutation was found in Dgcr2 in a human schizophrenic patient, 35 which suggests a possible involvement of Dgcr2 in the pathogenesis of schizophrenia. To examine whether or not Dgcr2 haplodeletion also causes behavioral abnormalities similar to that in Df1/ þ mice, we genetically engineered Dgcr2 KO mice by homologous recombination in embryonic stem cells. To introduce a targeted mutation in the mouse Dgcr2 gene, we constructed a targeting vector, in which the expression cassette of EGFP-SV40 polyA and the neomycin resistance (EGFP-Neo) gene was inserted in exon 1, which contains an initiation codon of Dgcr2 and flanked by the 5 0 5.6-kb and 3 0 1.2-kb Dgcr2 gene fragments ( Figure 2b ). This mutation is predicted to introduce a premature stop codon to all the transcripts of Dgcr2. The disrupted Dgcr2 allele was confirmed by Southern blot analysis ( Figure 2c ) and genomic PCR (data not shown). Dgcr2 À/À mice were backcrossed to the C57BL/6 for 10 generations before behavioral analysis. No Dgcr2 RNA transcript could be detected by RT-PCR in the brains of the mutant mice, validating Dgcr2 genetic disruption (Figure 2d ). Dgcr2 À/À mice were born according to Mendelian segregation, were viable and fertile, and visually indistinguishable from their wild-type littermates. Histopathological ) (e, g) and L655708 (5 or 15 mg kg À1 ) (f, g). Ambulatory distance is shown in 5 min bins for 60 min after drug administration (e-g) and quantification of ambulatory distance for 60 min is shown in (g). Values are the mean ± s.e.m. for 6-16 male mice. *P ¼ 0.0043. Figures 2e and f) . Therefore, we adopted Df1/ þ mice for further analysis.
Prefrontal cortical gene transfer of Comt in Df1/ þ mice. To examine whether the reduced expression of Comt is involved in behavioral defects of Df1/ þ mice, we bilaterally reintroduce mouse Comt to the prelimbic cortex and the infralimbic cortex of Df1/ þ mice by stereotactic injection of lentiviruses, using EGFP as a control (Figure 3a) . To distinguish cell type-specific effects of Comt overexpression, we utilized two types of lentivirus vectors, one of which is with a ubiquitous CMV/CAG promoter (Lenti-CAG-Comt) 36 and the other is with a neuron-specific CaMKII promoter (Lenti-CaMKII-Comt). Western blotting analysis showed that both membrane-bound and soluble forms of Comt were generated from the same mRNA derived from a lentivirus (Figure 3c ). Lentivirus-mediated specific expression of Comt in the PFC was confirmed by immunohistochemical analysis (Figure 3b ). Quantitative real-time PCR analysis showed that Comt expression reduced by 55% in the PFC of Df1 mice than that of control mice (P ¼ 0.0000068; Figure 3d ). After Lenti-CAG-Comt infection, Comt expression increased to B150% of that of EGFPexpressing control PFC in Df1/ þ mice (Figure 3d ). Immunofluorescent study showed that in Lenti-CAG-Comt-infected PFC, 19.43±1.63% of Comt-expressing cells were S100b-positive glial cells and 55.66±2.26% were NeuN-positive neurons, and 4.71 ± 1.94% were Gad67-positive interneurons (n ¼ 6), whereas in Lenti-CamKII-Comt-infected PFC, 1.99±1.11% of Comt-expressing cells were S100b-positive glial cells and 89.27 ± 2.21% were NeuN-positive neurons, and 15.69 ± 1.18% were Gad67-positive interneurons (n ¼ 3; Figure 3g ). The percentage of Lenti-CamKIIComt-transduced interneurons was 4 times higher than that observed with Lenti-CAG-Comt lentivirus. 
À1 tolcapone (i.p.) efficiently inhibited Comt activity in PFC, increased DOPAC level and decreased HVA level to a comparable level to that in control mice even in the Comt-overexpressed mice, whereas 6 mg kg À1 tolcapone administration was not sufficient ( Figure 5 ). Therefore, we adopted 30 mg kg À1 tolcapone for further experiments. However, 30 mg kg À1 of tolcapone failed to reverse the curing effects of PFC Comt overexpression. On the contrary, tolcapone administration of this dose even reduced the response of Comt-overexpressing Df1/ þ mice to MK801 but not to SKF38393 (MK801 þ tolcapone: stereotypy count for 60 min after administration, þ / þ ; 12 092.0±5551.9, Df1/ þ ; 6433.5±3121.1, P ¼ 0.049; Figures 4c and f) , suggesting that the indirect effects of increased Comt enzymatic activity might be responsible for its curing potential.
Comt overexpression normalized the abnormal responsiveness of Df1/ þ mice to GABA A receptor agonists. The enhanced response of EGFP-overexpressed Df1/ þ mice to MK801 or SKF38393 was also reversed by SL651498 administration as in non-virus-infected Df1/ þ mice (Figures 4b and e, and 6b and e) . In addition, Df1/ þ mice showed an abnormal response to bretazenil when treated with methamphetamine (1 mg kg À1 , i.p.; stereotypy count from 30 to 60 min after administration, Df1/ þ mice, methamphetamine, 4104.63±565.90, methamphetamine þ bretazenil 1984.60±721.46 (P ¼ 0.048); Figure 7c ). Next, we examined the effects of Lenti-CAG-Comt treatment on this GABAergic response abnormality of Df1/ þ mice. After Figure 7c ). These data suggest that the curing effect on the responsiveness to GABA A receptor agonists might also be a secondary effect of increasing Comt activity.
Comt overexpression enhanced the responsiveness to GABA A receptor agonists in control mice. We next examined the effects of PFC Comt overexpression on the behavioral responsiveness to GABA A receptor agonists in control mice. Lenti-CAG-Comt-infected mice showed enhanced responsiveness to a low dose of either bretazenil (10 mg kg À1 , i.p.) or SL651498 (1 mg kg À1 , i.p.) when treated with methamphetamine (1 mg kg À1 , i.p.) (stereotypy count, Lenti-CAG-Comt: methamphetamine; 4097.44 ± 537.31, methamphetamine þ bretazenil; 1749.00±640.53 (P ¼ 0.017), methamphetamine þ SL651498; 1664.71±895.29 (P ¼ 0.031); Figure 6a ), whereas in Lenti-CAG-GFP-infected control mice, this dose of SL651498 had no effect on the locomotor stimulating effects of methamphetamine (stereotypy count, Lenti-CAG-GFP: methamphetamine; 3113.67 ± 577.52, methamphetamine þ bretazenil; 3547.50 ± 875.70, P ¼ 0.73, methamphetamine þ SL651498; 3083.00± 1115.41, P ¼ 0.98; Figure 7a ). In addition, this effect of PFC Comt overexpression was also observed in mice infected by Lenti-CaMKII-Comt (stereotypy count, Lenti-CaMKII-Comt: methamphetamine; 3529.73±679.80, methamphetamine þ Figure 7a ). These data suggest that the differences in Comt expression level in interneurons and astrocytes did not influence the effects of Comt-expressing lentiviruses on the responsiveness to GABA A receptor agonists. This high responsiveness of Lenti-CAGComt or Lenti-CaMKII-Comt-infected mice to bretazenil is also resistant to tolcapone (stereotypy count, Lenti-CAGComt: methamphetamine þ bretazenil; 1749.000 ± 640.53, methamphetamine þ bretazenil þ tolcapone; 1628.08 ± 444.13, P ¼ 0.88, Lenti-CaMKII-Comt: methamphetamine þ bretazenil; 1310.09 ± 400.01, methamphetamine þ bretazenil þ tolcapone; 1743.36 ± 524.16, P ¼ 0.52; Figure 7b ), suggesting that the increasing Comt activity might indirectly cause an abnormal responsiveness to GABA A receptor agonists in control mice.
Comt inhibition enhanced the responsiveness to GABA A receptor agonists in wild-type mice. Furthermore, we found that inhibition of endogenous Comt activity by tolcapone enhanced the responsiveness to bretazenil in methamphetamine-induced hyperlocomotion of Lenti-CAG-GFP-infected wild-type mice (Lenti-CAG-GFP: methamphetamine þ bretazenil; 3547.50 ± 875.70, methamphetamine þ bretazenil þ tolcapone; 1523.30±355.24, P ¼ 0.046; Figure 7b ), whereas administration of tolcapone had no effects on locomotor effects of methamphetamine in Lenti-CAG-Comt, Lenti-CaMKII-Comt or Lenti-CAG-GFP-infected mice (Figure 7b ). These data demonstrated that both elevation and reduction in Comt expression lead to an abnormal responsiveness to GABA A receptor agonists.
Comt overexpression induced c-Fos expression specifically in GABAergic interneurons. It has been reported that NMDA antagonists increase PFC activity 37 and increase the expression of c-Fos specifically in pyramidal neurons but not in GABAergic interneurons. 38 To examine how increasing Comt expression affects PFC activity, we performed immunohistochemical analysis of c-Fos expression in the PFC of Lenti-CAG-Comt-, LentiCamKII-Comt-or Lenti-CAG-GFP-infected Df1/ þ and control mice. In the PFC of Lenti-CAG-Comt-or LentiCamKII-Comt-infected control mice, Comt overexpression increased the number of c- 
c-Fos
; Figures 8c  and d) . In Df1/ þ mice, PFC Comt overexpression also increased c-Fos expression in GABAergic interneurons (Df1/ þ mice: layer II/III, c-Fos
; Figures 8c and d) . These data indicate that increasing Comt expression in the PFC specifically enhance the activity of interneurons in both Df1/ þ and control mice.
Comt overexpression upregulated GABA signalingrelated genes in the PFC. To examine the effects of Comt overexpression on GABA signaling, we assessed the expression levels of GABA receptors and GABA signalingrelated genes at 2 weeks after infection by real-time PCR. We observed significant correlation between Comt expression and Gabrb2 (GABA A receptor b2), Gad2 (glutamic acid decarboxylase 65 (GAD65)) and Reln (reelin) in the PFC of Lenti-CAG-Comt-infected mice (Gabrb2: R ¼ 0.63, P ¼ 0.020, Gad2: R ¼ 0.63, P ¼ 0.020, and Reln: R ¼ 0.62, P ¼ 0.023; Figures 9a-c) . Similar effects were also observed in Lenti-CaMKII-Comt-infected mice (Gabrb2: R ¼ 0.85, P ¼ 0.0082, Gad2: R ¼ 0.91, P ¼ 0.0016, and Reln: R ¼ 0.66, P ¼ 0.077; Figures 9a-c) .
Next, we examined the effects of increasing Comt expression on GABAergic synapses in the PFC. GABA immunofluorescence in the prelimbic cortex was present as puncta rings around soma. Quantitative analysis of fluorescent pixel density of puncta rings showed that GABA immunofluorescence in perisomatic puncta was increased by Lenti-CAGComt or Lenti-CaMKII-Comt infection in both Df1/ þ and control mice (pixel density, þ / þ mice: Lenti-CAG-Comt; 1552.06±93.11 (P ¼ 0.026), Lenti-CaMKII-Comt; 1638.72± 67.61 (P ¼ 0.0067), Lenti-CAG-GFP; 1169.67±60.57; Figures 3d, e, g and h) . However, there was no change in the density of Gad67 ). These data showed that Comt overexpression enhanced GABA production without affecting the number of GABAergic interneurons and that the differences in the Comt expression levels in interneurons 
Discussion
Df1/ þ mice displayed higher locomotive activity to psychostimulants, similar to human schizophrenic patients. Our pharmacological data suggest that GABA signaling abnormalities are involved in these behavioral abnormalities of Df1/ þ mice. Lentivirus-mediated Comt reintroduction to the PFC of Df1/ þ mice normalized the abnormal responses of Df1/ þ mice to GABA A receptor agonists as well as to psychostimulants. In contrast, in wild-type mice, increased Comt expression in the PFC caused abnormal responses to GABA A receptor agonists. A Comt inhibitor, tolcapone, failed to reverse the curing effect of Comt overexpression on behavioral abnormalities of Df1/ þ mice, indicating that the effects do not directly result from increased Comt enzymatic activity in the PFC. Comt overexpression in the PFC upregulated GABA signaling-related genes, which might explain the effects of Comt overexpression on GABA signaling. Furthermore, we showed PFC Comt expression increased c-Fos expression specifically in GABAergic interneurons and enhanced MK801-induced GABA release.
Deficits in the GABAergic system are thought to be one of the prominent pathologies of schizophrenia. [32] [33] [34] Postmortem studies of the brains of schizophrenic patients showed reduction in the 67 kDa isoform of GAD (GAD67), which is an enzyme responsible for GABA synthesis. 39, 40 GAD67 reduction is observed specifically in chandelier cells. 41 Decrease in GABA reuptake transporter and upregulation of GABA A a2 receptor are also observed at chandelier cell synapse of schizophrenic patients, which might compensate the reduction of GABAergic transmission caused by GAD67 reduction. [42] [43] [44] The abnormal development of parvalbumin-positive interneurons including chandelier cells has been shown in a different mouse model of 22q11DS. 45 Our data showed the abnormal responsiveness of Df1/ þ mice to a GABA A receptor agonist (bretazenil) and a GABA A receptor a2/a3 agonist (SL651498) in psychostimulant-induced hyperlocomotion. Comt overexpression in the PFC not only normalized abnormal responsiveness of Df1/ þ mice to psychostimulants, but also attenuated the abnormal responsiveness to GABA A receptor agonist. Our studies also demonstrated that increasing Comt activity in the PFC caused upregulation of GABA-related genes such as Gabrb2, Gad2 and Reln. Single-nucleotide polymorphisms of RELN and GABRB2 are known to associated with risks for schizophrenia. 46, 47 Reln is reported to be expressed in GABAergic neurons, and affects the composition of NMDA receptors. 48 NMDA receptors regulate the activity of fast-spiking interneurons, and NMDA antagonists decrease the activity of interneurons in the PFC, leading to excitation of cortical pyramidal neurons by disinhibition. 49 Increase in GABA level at the interneuronal synapses and GABA release was observed in PFC Comt-overexpressing mice, which might be caused by increased level of Gad2. This enhanced GABA transmission might be responsible for the treatment effects of Comt overexpression. Our finding of the regulation of GABA signaling by Comt is consistent with a previous report that shows the genetic association of COMT with cortical GABA level. 50 DA is known to modulate GABA transmission in multiple brain regions. Electrically evoked GABA release was reduced by D2 agonists in the PFC and the striatum, 51, 52 but spontaneous release of GABA was increased by D2 agonists in the PFC. 52 Electrophysiological studies have shown that DA produces an initial reduction in inhibitory postsynaptic current in PFC pyramidal neurons through the reduction in GABA release, probability mediated by D2 receptor, followed by a long-lasting increase in inhibitory postsynaptic current amplitude, which is mainly mediated by D1 receptor. 53 Different effects of DA on GABA transmission have been reported, and the molecular mechanism of the effects of Comt overexpression on GABA transmission remains to be elucidated.
A COMT low-activity allele is identified as a risk factor for impaired cognitive function and psychiatric symptoms in adolescence in 22q11DS. [14] [15] [16] [17] Epistatic interaction between Comt and Prodh is known to modulate schizophrenia-like phenotypes in mice. 7 Our data are consistent with these findings. Our studies demonstrate that Comt overexpression in the PFC has a curing effect on Df1/ þ mice and that Comt has dual roles in the regulation of responsiveness to GABA A receptor agonists. The high Comt activity enhanced the GABA production and GABA release in the PFC and increased the responsiveness to GABA A receptor agonists, whereas endogenous relatively low Comt activity seemed to have the opposite effects, because a Comt inhibitor increased the responsiveness to GABA A receptor agonist in methamphetamine-induced locomotion of control mice. This phenotype of tolcapone-treated mice is similar to Df1/ þ mice, which have Comt heterozygosity. It is tempting to speculate the existence of inverted U-shaped relationship between Comtregulated cortical DA level and GABA transmissional regulation.
Our pharmacological data suggest that GABA A a2/a3 receptor might be a therapeutic target for psychiatric symptoms of 22q11DS, although conflicting results were obtained for therapeutic effects of GABA A a2/a3 receptor agonist for general schizophrenia. 54, 55 Schizophrenia is considered to be a heterogeneous group of disorders, and individual tailor-made drug treatment might be required for effective treatment of schizophrenia patients according to the disease etiology. In addition, pharmacological treatments to increase Comt expression or activity also can be used to reduce or prevent psychiatric symptoms of 22q11DS. However, therapeutic intervention should take into account the dual roles of Comt in the regulation of GABA transmission.
